Chordia Therapeutics (TSE:190A) EBITDA Margin %: 0.00% (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
11 GF Score
Price 円77.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics EBITDA Margin %?

Chordia Therapeutics TSE:190A -2.53% 11 EBITDA Margin % is 0.00% as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 940 Biotechnology companies, Chordia Therapeutics ranks worse than 106382.87% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Chordia Therapeutics's EBITDA for the six months ended in Feb. 2026 was 円-662.73 Mil. Chordia Therapeutics's Revenue for the six months ended in Feb. 2026 was 円0.00 Mil. Therefore, Chordia Therapeutics's EBITDA margin for the quarter that ended in Feb. 2026 was 0.00%.

Chordia Therapeutics  (TSE:190A) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Chordia Therapeutics EBITDA Margin % Related Terms

Chordia Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics EBITDA Margin % Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
EBITDA Margin %
-85.88 0.00 8.72 0.00 0.00

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
EBITDA Margin % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

TSE:190A vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Chordia Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chordia Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Chordia Therapeutics's EBITDA Margin % falls into.


TSE:190A
11GF Score
Chordia Therapeutics Inc TSE:190A
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Chordia Therapeutics's EBITDA Margin % for the fiscal year that ended in Aug. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Aug. 2025 )/Revenue (A: Aug. 2025 )
=-1787.078/0
= %

Chordia Therapeutics's EBITDA Margin % for the quarter that ended in Feb. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Feb. 2026 )/Revenue (Q: Feb. 2026 )
=-662.726/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Chordia Therapeutics (TSE:190A) has a EBITDA Margin % of 0.00% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chordia Therapeutics and its competitors. According to the industry distribution chart, Chordia Therapeutics ranks #999999 out of 940 companies in the Biotechnology industry.
Is Chordia Therapeutics' EBITDA Margin % too high?
Chordia Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Chordia Therapeutics ranks #999999 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chordia Therapeutics ranks #999999 out of 940 companies for EBITDA Margin %. This places Chordia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current EBITDA Margin % is 0.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score

Get the complete analysis for TSE:190A

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price